Genmab — Oktober 2017
-
GEN har indkaldt til online investorsnak d. 8. november, vedr. Q3.
-
Ja, lige nu havde det næsten været federe, men en snak om mulig overtagelse
-
Bliver den shortet lidt i øjeblikket også??
-
Det vil der altid være en risiko for på populære aktier. Medmindre du er shorttrader, så hav ro på, fordi casen er uændret.
-
REVLIMID
sales for the third quarter increased 10 percent to $2,081 million. Sales growth was driven primarily by increased volume, as a result of increases in duration and market share. U.S. sales of $1,361 million and international sales of $720 million increased 18 percent and decreased 2 percent year-over-year, respectively. -
POMALYST
/IMNOVID sales for the third quarter were $417 million, an increase of 22 percent year-over-year. U.S. sales were $268 million and international sales were $149 million, an increase of 32 percent and 8 percent year-over-year, respectively. POMALYST/IMNOVID sales growth was driven primarily by increased volume as a result of increases in market share and duration. -
Celgene is down 15% in premarket!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind